1. US FDA. (2009). Guidance for industry. Patient-reported outcomes measures: Use in medical product development to support labeling claims. Federal Registrer, 74(35), 65132–65133.
2. Acquadro, C., Berzon, R., Dubois, D., et al. (2001). Incorporating the patient’s perspective into drug development and communication: An ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration. Value in Health, 16, 522–531.
3. Au, H.-J., Ringash, J., Brundage, M., et al. Added value of health-related quality of life measurement in cancer clinical trials: The experience of the NCIC CTG. Expert Review of Pharmacoeconomics & Outcomes Research 10(2), 119–128, 2010.
4. Till, J. E., Osoba, D., Pater, J. L., & Young, J. R. (1994). Research on health-related quality of life: Dissemination into practical applications. Quality of Life Research, 3, 279–283.
5. Lipscomb, J., Gotay, C., & Snyder, C. (2005). Outcomes assessment in cancer: Measures, methods, and applications. Cambridge: Cambridge University Press.